Atricure, INC 10-Q quarterly reports

AtriCure Inc. announced its Q2 2026 financial results, showcasing a 13.5% increase in worldwide revenue to $294.9 million, driven by strong performance in key product lines.

AtriCure Inc. announced its first quarter 2026 financial results, showcasing a 14.3% increase in worldwide revenue to $141.2 million, driven by strong performance in its pain and appendage management product lines.

AtriCure, Inc. reported significantly reduced net losses and strong revenue growth for the third quarter and first nine months of 2025, driven by key product lines and international expansion.

AtriCure, Inc. announced robust revenue growth and a significant reduction in net loss for the second quarter and first half of 2025, fueled by strong performance in appendage and pain management product lines and advancements in clinical trials.

AtriCure, Inc. announces a 13.6% increase in worldwide revenue for Q1 2025, driven by product innovation, clinical science, and physician education.

AtriCure's Q3 2024 results show a 17.9% increase in worldwide revenue, fueled by product innovation and global market expansion.

AtriCure's second quarter 2024 results show a strong 15.8% increase in global revenue, fueled by growth across key product lines and strategic initiatives.

AtriCure's first quarter 2024 revenue increased by 16.4% year-over-year, driven by growth across key product lines and international sales.